Exenatide

Byetta, Bydureon

Grade B: Human evidence, not approved for this use

TL;DR: Exenatide was the first GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Byetta, twice-daily, in 2005; Bydureon, once-weekly extended-release, in 2012) and amassed substantial human RCT evidence across multiple large trials before market withdrawal. The EXSCEL cardiovascular outcomes trial, enrolling over 14,000 patients with type 2 diabetes, demonstrated non-inferiority to placebo for MACE but did not show superiority. Both branded formulations, Byetta and Bydureon BCise, were voluntarily withdrawn from the US market by AstraZeneca in October 2024 for commercial rather than safety reasons. The drug retains grade B status because extensive human RCT evidence exists, including cardiovascular outcomes data, but it is no longer available as an approved marketed product in the United States. Evidence from the exenatide program contributed to the understanding of the entire GLP-1 drug class.

Key Takeaways

Grade B: Human evidence, not approved for this use
Withdrawn: Previously approved as Byetta (twice-daily subcutaneous injection, type 2 diabetes, 2005) and Bydureon/Bydureon BCise (once-weekly extended-release subcutaneous injection, type 2 diabetes, 2012); both formulations voluntarily withdrawn from the US market in October 2024.
Compounding: Withdrawn from the US market; both Byetta (exenatide twice-daily injection) and Bydureon BCise (exenatide extended-release once-weekly) were discontinued by AstraZeneca as of October 2024. Not currently available by prescription in the United States. Compounding of a withdrawn drug from bulk API is not permitted under standard FDA compounding rules.

Exenatide chemical structure — Structure via PubChem CID 45588096

Mechanism

Exenatide is a synthetic exendin-4-based GLP-1 receptor agonist that stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite.

Evidence

Exenatide was the first GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Byetta, twice-daily, in 2005; Bydureon, once-weekly extended-release, in 2012) and amassed substantial human RCT evidence across multiple large trials before market withdrawal. The EXSCEL cardiovascular outcomes trial, enrolling over 14,000 patients with type 2 diabetes, demonstrated non-inferiority to placebo for MACE but did not show superiority. Both branded formulations, Byetta and Bydureon BCise, were voluntarily withdrawn from the US market by AstraZeneca in October 2024 for commercial rather than safety reasons. The drug retains grade B status because extensive human RCT evidence exists, including cardiovascular outcomes data, but it is no longer available as an approved marketed product in the United States. Evidence from the exenatide program contributed to the understanding of the entire GLP-1 drug class.

Safety and risks

Byetta (twice-daily immediate-release exenatide) does not carry a thyroid C-cell tumor boxed warning; the rodent carcinogenicity signal was not observed at clinical exposure margins for the short-acting formulation. However, Bydureon/Bydureon BCise (once-weekly extended-release exenatide) did carry a boxed warning for thyroid C-cell tumors in rats, consistent with other longer-acting GLP-1 agents; it was contraindicated in patients with a personal or family history of MTC or MEN 2. Pancreatitis, including fatal and non-fatal hemorrhagic and necrotizing cases, was reported in clinical trials and postmarketing; an FDA communication highlighted this risk in 2007. Acute kidney injury, in some cases requiring hemodialysis or kidney transplantation, has been reported in postmarketing experience; exenatide should not be used in severe renal impairment or end-stage renal disease. Hypoglycemia risk is elevated with concomitant insulin secretagogues. Gastrointestinal side effects including nausea, vomiting, and diarrhea are common and the primary reason for discontinuation. Both formulations are no longer available in the US market.

Interactions

Elevated hypoglycemia risk when combined with sulfonylureas or insulin. Slowed gastric emptying can reduce peak plasma concentrations of orally administered drugs; time-sensitive medications such as antibiotics or contraceptives should be taken at least one hour before exenatide.

Federal compounding status

FDA-approved drug as of 2026-06-02.

An FDA-approved drug that should be obtained as the licensed product. It is not a 503A bulk-substance candidate; compounding from bulk is limited under federal rules and generally permitted only during a declared shortage.

Federal status only, from public FDA records. State pharmacy-board rules vary and are not covered here. This is regulatory reporting, not legal advice. All compounds.

Compounding legality

Withdrawn from the US market; both Byetta (exenatide twice-daily injection) and Bydureon BCise (exenatide extended-release once-weekly) were discontinued by AstraZeneca as of October 2024. Not currently available by prescription in the United States. Compounding of a withdrawn drug from bulk API is not permitted under standard FDA compounding rules.

Sources

Exenatide is Withdrawn. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 1, 2026 by PeptideGrids editorial team (independently audited).